exRNAdisease

Entry Detail

---



General Information

Database ID: exR0274845 RNA Name: hsa-miR-491-5p RNA Type: miRNA Chromosome: chr9 Starnd: + Coordinate: Start Site(bp): 20716120 End Site(bp): 20716141 External Links: hsa-miR-491-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE22981 Description: Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: Early satge breast cancer Case Sample: Breast Cancer Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand IGFBP4 chr17 40443450 40457725 + SRF chr6 43171269 43181506 + CDR2L chr17 74987632 75005800 + CENPB chr20 3783851 3786740 - RBFOX2 chr22 35738736 36028824 - SPRED2 chr2 65310851 65432637 - PHB2 chr12 6965327 6970753 - PTPRU chr1 29236516 29326813 + PTBP3 chr9 112217716 112333667 - SLC6A6 chr3 14402576 14489349 + SNAI1 chr20 49982980 49988886 + NDST1 chr5 150485818 150558211 + PPP4C chr16 30075978 30085376 + LIMD2 chr17 63695888 63701172 - TTPAL chr20 44475874 44494603 + SAMD4B chr19 39342396 39385710 + QSOX2 chr9 136206333 136245812 - C19orf47 chr19 40319536 40348527 - ZNF574 chr19 42068477 42081552 + PDXP chr22 37658723 37666932 + MEF2D chr1 156463727 156500779 - TP53 chr17 7661779 7687550 - ATXN7L3 chr17 44191805 44200113 - CPSF7 chr11 61402641 61430031 - CD151 chr11 832887 839831 + DIRAS1 chr19 2714567 2721372 - COL4A2 chr13 110305812 110513209 + NOTCH2 chr1 119911553 120100779 - INTS2 chr17 61865367 61928016 - HDGF chr1 156742109 156766925 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000128 chr1 151139409 151139890 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC016876.2 chr17 7581964 7584086 - AC023509.1 chr12 53441741 53467528 + AC069281.2 chr7 100572232 100578700 - AL355987.2 chr9 136800366 136829466 + AL645608.6 chr1 904834 915976 + H19 chr11 1995176 2001470 - LINC01278 chrX 63222993 63561095 - MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + PCBP2-OT1 chr12 53464468 53465057 + VPS9D1-AS1 chr16 89711856 89718165 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE22981 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 801 Sample treatment protocol: NA RNA Extract protocol: Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications. RNA library preparation protocol: Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).

Reference

PMID: 21060830 Title: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer Author: Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer. Journal: PLoS One. 2010 Oct 29;5(10):e13735. Description: The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.